17:52 , Aug 10, 2017 |  BC Innovations  |  Emerging Company Profile

Flexing against suppression

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...
19:40 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Dermatology; inflammation

INDICATION: Dermatitis; allergy Cell culture and mouse studies suggest morpholino oligomers that exclude exon 3 from the FCER1B transcript could help treat allergy and allergic dermatitis. In activated primary mouse bone marrow-derived mast cells, a...
07:00 , Jun 9, 2011 |  BC Innovations  |  Targets & Mechanisms

Short-circuiting DCs in atherosclerosis

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes...
07:00 , Jun 9, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Chemokine CC motif ligand 17 (CCL17) Mouse studies suggest antagonizing CCL17 could help treat atherosclerosis. In a mouse...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

IMA901: Additional Phase II data

Additional data from the open-label, exploratory, European Phase II IMA901-202 trial in 61 evaluable patients with advanced or metastatic RCC who had failed previous first-line therapy showed that intradermal IMA901 led to significantly greater survival...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Affitech, Cancer Research U.K. deal

Affitech received exclusive, worldwide rights from Cancer Research's Cancer Research Technology Ltd. commercial arm to a patent application and IP to develop antibodies against tumor protein CC chemokine receptor 4 (CCR4; CD194 ). Affitech said...